STARTERNCT06352307
Clinical Phenotypes, Natural History, and Long-Term Outcomes of Arrhythmogenic Cardiomyopathy: The STARTER Registry
At risk: Primary completion moved 20 years 4 months later, primary endpoint(s) modified.
See at-risk trials from First Affiliated Hospital Xi'an Jiaotong University
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Dec 31, 2050 Show 9 more changesShow less
- Primary endpoint(s) modified
- Enrollment increased: 1500 → 4500 participants
- Eligibility criteria expanded, about 269 words
- Interventions modified
- Trial arms changed: 3 → 2
- Secondary endpoints expanded, about 104 words
- Study description expanded, about 400 words
- Site details revised
- Study title expanded, about 3 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Dec 31, 2024 to Apr 9, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (17)
Show 12 moreShow less
Arms and interventions
Patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) and available medical records from January 1, 2018, through October 1, 2026, will be included retrospectively. Existing clinical data, including medical history, ventricular phenotype, electrocardiographic findings, cardiac imaging, genetic testing results when available, treatments, and documented clinical outcomes, will be collected and analyzed. Patients will be classified according to right-dominant, left-dominant, or biventricular ACM phenotypes. No research-specific interventions, additional examinations, or new biospecimen collection will be performed as part of retrospective data collection.
Patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) will be prospectively enrolled and followed under routine clinical care. Clinical, electrocardiographic, imaging, genetic, treatment, and outcome data will be collected. Patients will be classified as having right-dominant, left-dominant, or biventricular ACM. Follow-up will generally occur at 6 months, 12 months, and annually during years 2 through 5 to assess serious ventricular arrhythmias, sudden cardiac death, heart failure-related events, and changes in cardiac phenotype. Optional biospecimens may be collected with appropriate consent and ethical approval. No experimental treatments or research-mandated invasive procedures will be performed.
Sites
1 site in 1 country
- First Affiliated Hospital of Xi'an Jiantong UniversityXi'an, Shaanxi, China